ARCTICZYMES TECHNOLOGIES ASA (AZT.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:AZT - NO0010014632 - Common Stock
21.8 NOK
+0.1 (+0.46%)
AZT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 82 industry peers in the Biotechnology industry. While AZT has a great health rating, its profitability is only average at the moment. AZT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year AZT was profitable.
AZT had a positive operating cash flow in the past year.
Each year in the past 5 years AZT has been profitable.
Each year in the past 5 years AZT had a positive operating cash flow.
1.2 Ratios
The Return On Assets of AZT (0.80%) is better than 68.67% of its industry peers.
AZT has a better Return On Equity (0.86%) than 72.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.8% | ||
| ROE | 0.86% | ||
| ROIC | N/A |
ROA(3y)6.16%
ROA(5y)14.45%
ROE(3y)6.81%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 2.86%, AZT is doing good in the industry, outperforming 74.70% of the companies in the same industry.
AZT's Profit Margin has declined in the last couple of years.
AZT has a Gross Margin of 94.85%. This is amongst the best in the industry. AZT outperforms 92.77% of its industry peers.
AZT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 2.86% | ||
| GM | 94.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-39.27%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
2. Health
2.1 Basic Checks
AZT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AZT has been increased compared to 1 year ago.
AZT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AZT has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 30.41 indicates that AZT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 30.41, AZT belongs to the best of the industry, outperforming 96.39% of the companies in the same industry.
AZT has a debt to FCF ratio of 1.29. This is a very positive value and a sign of high solvency as it would only need 1.29 years to pay back of all of its debts.
AZT's Debt to FCF ratio of 1.29 is amongst the best of the industry. AZT outperforms 87.95% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that AZT is not too dependend on debt financing.
AZT's Debt to Equity ratio of 0.01 is fine compared to the rest of the industry. AZT outperforms 78.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 1.29 | ||
| Altman-Z | 30.41 |
ROIC/WACCN/A
WACC8.52%
2.3 Liquidity
AZT has a Current Ratio of 15.90. This indicates that AZT is financially healthy and has no problem in meeting its short term obligations.
AZT has a better Current ratio (15.90) than 97.59% of its industry peers.
A Quick Ratio of 15.02 indicates that AZT has no problem at all paying its short term obligations.
The Quick ratio of AZT (15.02) is better than 97.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.9 | ||
| Quick Ratio | 15.02 |
3. Growth
3.1 Past
The earnings per share for AZT have decreased by 0.00% in the last year.
AZT shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -43.42% yearly.
Looking at the last year, AZT shows a very negative growth in Revenue. The Revenue has decreased by -12.26% in the last year.
Measured over the past years, AZT shows a quite strong growth in Revenue. The Revenue has been growing by 18.22% on average per year.
EPS 1Y (TTM)0%
EPS 3Y-43.42%
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)-12.26%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%22.3%
3.2 Future
Based on estimates for the next years, AZT will show a very strong growth in Earnings Per Share. The EPS will grow by 73.58% on average per year.
Based on estimates for the next years, AZT will show a quite strong growth in Revenue. The Revenue will grow by 18.45% on average per year.
EPS Next Y-2.61%
EPS Next 2Y81.18%
EPS Next 3Y73.58%
EPS Next 5YN/A
Revenue Next Year4.69%
Revenue Next 2Y15.27%
Revenue Next 3Y16.06%
Revenue Next 5Y18.45%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
AZT is valuated quite expensively with a Price/Earnings ratio of 181.67.
Based on the Price/Earnings ratio, AZT is valued a bit cheaper than 71.08% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.39, AZT is valued quite expensively.
AZT is valuated quite expensively with a Price/Forward Earnings ratio of 47.44.
75.90% of the companies in the same industry are more expensive than AZT, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.84, AZT is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 181.67 | ||
| Fwd PE | 47.44 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AZT indicates a somewhat cheap valuation: AZT is cheaper than 65.06% of the companies listed in the same industry.
74.70% of the companies in the same industry are more expensive than AZT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 202.61 | ||
| EV/EBITDA | 1879.05 |
4.3 Compensation for Growth
A more expensive valuation may be justified as AZT's earnings are expected to grow with 73.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y81.18%
EPS Next 3Y73.58%
5. Dividend
5.1 Amount
AZT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
OSL:AZT (12/19/2025, 7:00:00 PM)
21.8
+0.1 (+0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners16.46%
Inst Owner ChangeN/A
Ins Owners0.37%
Ins Owner ChangeN/A
Market Cap1.11B
Revenue(TTM)104.35M
Net Income(TTM)2.80M
Analysts80
Price Target33.66 (54.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-36.35%
Min EPS beat(2)-269.73%
Max EPS beat(2)197.03%
EPS beat(4)2
Avg EPS beat(4)268.95%
Min EPS beat(4)-269.73%
Max EPS beat(4)1288.12%
EPS beat(8)3
Avg EPS beat(8)136.16%
EPS beat(12)4
Avg EPS beat(12)79.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-5.61%
Min Revenue beat(2)-13.1%
Max Revenue beat(2)1.89%
Revenue beat(4)2
Avg Revenue beat(4)-6.89%
Min Revenue beat(4)-18.99%
Max Revenue beat(4)2.64%
Revenue beat(8)3
Avg Revenue beat(8)-5.33%
Revenue beat(12)3
Avg Revenue beat(12)-6.56%
Revenue beat(16)6
Avg Revenue beat(16)-2.7%
PT rev (1m)-2.94%
PT rev (3m)17.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)-3.57%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.76%
Revenue NY rev (1m)-2.62%
Revenue NY rev (3m)-4.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 181.67 | ||
| Fwd PE | 47.44 | ||
| P/S | 11.38 | ||
| P/FCF | 202.61 | ||
| P/OCF | 105.53 | ||
| P/B | 3.41 | ||
| P/tB | 3.81 | ||
| EV/EBITDA | 1879.05 |
EPS(TTM)0.12
EY0.55%
EPS(NY)0.46
Fwd EY2.11%
FCF(TTM)0.11
FCFY0.49%
OCF(TTM)0.21
OCFY0.95%
SpS1.92
BVpS6.39
TBVpS5.72
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.15
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.8% | ||
| ROE | 0.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 2.86% | ||
| GM | 94.85% | ||
| FCFM | 5.61% |
ROA(3y)6.16%
ROA(5y)14.45%
ROE(3y)6.81%
ROE(5y)16.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-39.27%
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.64%
F-Score5
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 1.29 | ||
| Debt/EBITDA | 10.86 | ||
| Cap/Depr | 62.51% | ||
| Cap/Sales | 5.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 2482.35% | ||
| Profit Quality | 195.97% | ||
| Current Ratio | 15.9 | ||
| Quick Ratio | 15.02 | ||
| Altman-Z | 30.41 |
F-Score5
WACC8.52%
ROIC/WACCN/A
Cap/Depr(3y)231.16%
Cap/Depr(5y)215.23%
Cap/Sales(3y)11.45%
Cap/Sales(5y)9.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y-43.42%
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y-2.61%
EPS Next 2Y81.18%
EPS Next 3Y73.58%
EPS Next 5YN/A
Revenue 1Y (TTM)-12.26%
Revenue growth 3Y-6.57%
Revenue growth 5Y18.22%
Sales Q2Q%22.3%
Revenue Next Year4.69%
Revenue Next 2Y15.27%
Revenue Next 3Y16.06%
Revenue Next 5Y18.45%
EBIT growth 1Y-196.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year328.57%
EBIT Next 3Y149.71%
EBIT Next 5YN/A
FCF growth 1Y-33.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.1%
OCF growth 3Y-71.92%
OCF growth 5Y-16%
ARCTICZYMES TECHNOLOGIES ASA / AZT.OL FAQ
What is the ChartMill fundamental rating of ARCTICZYMES TECHNOLOGIES ASA (AZT.OL) stock?
ChartMill assigns a fundamental rating of 5 / 10 to AZT.OL.
Can you provide the valuation status for ARCTICZYMES TECHNOLOGIES ASA?
ChartMill assigns a valuation rating of 4 / 10 to ARCTICZYMES TECHNOLOGIES ASA (AZT.OL). This can be considered as Fairly Valued.
What is the profitability of AZT stock?
ARCTICZYMES TECHNOLOGIES ASA (AZT.OL) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for AZT stock?
The Earnings per Share (EPS) of ARCTICZYMES TECHNOLOGIES ASA (AZT.OL) is expected to decline by -2.61% in the next year.